| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/17/2006 | US6987098 Health supplement |
| 01/17/2006 | US6987092 Indigoid bisindole derivatives |
| 01/17/2006 | US6987091 Sir2 products and activities |
| 01/17/2006 | US6987088 Novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the |
| 01/17/2006 | US6987024 Human ovarian mesothelial cells and methods of isolation and uses thereof |
| 01/17/2006 | US6987014 Isolated nucleic acid molecules encoding human drug metabolizing proteins |
| 01/17/2006 | US6986996 Using anti-heparanase antibody to bind heparanase encoded by amino acid sequence no.1 for monitoring heparanase protein expression of heparanase gene in white blood cells in vitro; drug delivery targets; diagnosis of tumors, cancer and metastasis |
| 01/17/2006 | US6986891 Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof |
| 01/17/2006 | US6986740 administering an ultrasound contrast agent such as Rose Bengal; a portion of the contrast agent being retained in tissue of interest; and imaging the tissue with ultrasound to identify the tissue |
| 01/17/2006 | CA2362394C Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
| 01/17/2006 | CA2147567C Improvements in platinum complexes |
| 01/12/2006 | WO2006003289A2 Sulphated polysaccharide derivatives for modulating angiogenesis |
| 01/12/2006 | WO2006003276A1 Substituted indazoles, compositions containing same, preparation and use |
| 01/12/2006 | WO2006002889A2 Improved adjuvant therapy of g250-expressing tumors |
| 01/12/2006 | WO2003089596A3 Novel prostate tumor-specific promoter |
| 01/12/2006 | US20060009528 Cannabinoid receptor ligands |
| 01/12/2006 | US20060009527 Method of treating TRX mediated diseases |
| 01/12/2006 | US20060009526 Method of treating TRX mediated diseases |
| 01/12/2006 | US20060009525 Hydroxamic acids and acyl hydroxamines as NAALADase inhibitors |
| 01/12/2006 | US20060009521 Lipoxin analogs as novel inhibitors of angiogenesis |
| 01/12/2006 | US20060009517 Tricyclic inhibitors of poly(ADP-ribose) polymerases |
| 01/12/2006 | US20060009513 Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use |
| 01/12/2006 | US20060009505 Anti-cancer composition comprising DMXAA or related compound |
| 01/12/2006 | US20060009495 Diary 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 01/12/2006 | US20060009492 Cancer treatment with compounds inhibiting PKC alpha |
| 01/12/2006 | US20060009482 Screening method for identifying compounds that selectively induce interferon alpha |
| 01/12/2006 | US20060009475 Quinazolinone compounds in combined modalities for improved cancer treatment |
| 01/12/2006 | US20060009462 Prodrugs of CC-1065 analogs |
| 01/12/2006 | US20060009445 Tumor-inhibiting anellated azepinone derivatives |
| 01/12/2006 | US20060009440 Heterocyclic compounds and antitumor drugs containing the same as the active ingredient |
| 01/12/2006 | US20060009439 Novel physiologically active substances |
| 01/12/2006 | US20060009436 11 beta -Fluoro-7 alpha -{5-[methyl(7,7,8,8,9,9,9-heptafluorononyl)amino]pentyl}-17 alpha -methylestra-1,3,5(10)-triene-3,17 beta -diol N-oxide; antiestrogen compound whose metabolism can be controlled; alveolar macrophages do not build up; oral administration |
| 01/12/2006 | US20060009418 Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
| 01/12/2006 | US20060009412 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src |
| 01/12/2006 | US20060009409 Double-stranded oligonucleotides |
| 01/12/2006 | US20060009405 Bispecific Oligonucleotide for the Treatment of CNS Malignancies |
| 01/12/2006 | US20060009403 Dna demethylase antisense and chemotherapy combination |
| 01/12/2006 | US20060009402 Engineered RNA precursors encoded in plasmids and/or other vectors; simple, low cost technique utilizing DNA molecule production; host cells, transgenes |
| 01/12/2006 | US20060009380 Isolated deoxyribonucleic acid fragment that codes for the calcium binding proteins; treating skin disorders, like dry skin, hyperkeratosis, parakeratosis, psoriasis, ichthyosis, and neoplasia; cosmetics |
| 01/12/2006 | US20060009375 Site-specific drug delivery |
| 01/12/2006 | US20060008889 Phosphatase specific immunoglobulin for use in diagnosis, prevention and treatment of cell proliferative, autoimmune, muscular and graft vs. host diseases |
| 01/12/2006 | US20060008574 Galactosyl isomalt, method for production and use thereof |
| 01/12/2006 | US20060008478 Immunoadjuvant |
| 01/12/2006 | US20060008471 Organ, tissue and cell-specific immuno-therapeutic for chronic viral infections and inflammatory, degenerative and proliferative diseases, in particular of the liver, and for cancer, based on a recombinant parapox virus |
| 01/12/2006 | US20060008465 Novel methods for therapeutic vaccination |
| 01/12/2006 | DE19961182B4 Galactomannan-Oligosaccharide und Verfahren zu deren Herstellung sowie deren Verwendung Galactomannan oligosaccharides and processes for their preparation and their use |
| 01/12/2006 | DE19925211B4 Kit zur Herstellung einer Formulierung von Paclitaxel Kit for preparing a formulation of paclitaxel |
| 01/12/2006 | CA2572872A1 Tissue factor production inhibitor |
| 01/12/2006 | CA2572321A1 Anti-synoviolin antibody |
| 01/12/2006 | CA2572314A1 Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity |
| 01/12/2006 | CA2572058A1 Azaindoles useful as inhibitors of protein kinases |
| 01/12/2006 | CA2571738A1 Thiazolinone unsubstituted quinolines |
| 01/12/2006 | CA2571732A1 Quinoline thiazolinones with cdk1 antiproliferative activity |
| 01/12/2006 | CA2571440A1 Use of steroid-derived pharmaceutical compositions for treating disorders relating to pathological processes in lipid rafts |
| 01/12/2006 | CA2570533A1 Substituted hydroxyacetophenon derivatives |
| 01/12/2006 | CA2570213A1 Alpha-helical mimetics |
| 01/12/2006 | CA2570191A1 Radionuclides for medical use |
| 01/12/2006 | CA2570169A1 Azine-carboxamides as anti-cancer agent |
| 01/12/2006 | CA2569827A1 Quinazolinedione derivatives as parp inhibitors |
| 01/12/2006 | CA2569679A1 Conjugates of antibody and duoarmycin derivatives as antitumor agents |
| 01/12/2006 | CA2567744A1 Substituted indazoles, compositions containing same, preparation and use |
| 01/12/2006 | CA2566950A1 Improved adjuvant therapy of g250-expressing tumors |
| 01/11/2006 | EP1614697A1 Proteoglycan isolated from cartilaginous fish and process for producing the same |
| 01/11/2006 | EP1614694A1 Titanium dioxide complex having molecule distinguishability |
| 01/11/2006 | EP1614688A1 Phenylazole compound, production process, and antioxidant drug |
| 01/11/2006 | EP1614684A1 Diamine derivative, production process, and antioxidizing drug |
| 01/11/2006 | EP1614683A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| 01/11/2006 | EP1614680A2 Process for preparing 2-iminopyrrolidine derivatives |
| 01/11/2006 | EP1614414A2 Compositions comprising a copper compound for treatment of mammalian diseases |
| 01/11/2006 | EP1613775A2 Selected rna motifs to include cell death and/or apoptosis |
| 01/11/2006 | EP1613750A2 Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
| 01/11/2006 | EP1613660A2 Compositions and methods relating to stop-1 |
| 01/11/2006 | EP1613658A2 Antibodies against insulin-like growth factor i receptor and uses thereof |
| 01/11/2006 | EP1613656A1 Cancerous disease modifying antibodies |
| 01/11/2006 | EP1613628A2 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 01/11/2006 | EP1613627A1 7-azaindoles and use thereof as therapeutic agents |
| 01/11/2006 | EP1613623A1 Novel oxazole derivatives, their manufacture and use as pharmaceutical agents |
| 01/11/2006 | EP1613622A1 Oxime derivatives and their use as pharmaceutically active agents |
| 01/11/2006 | EP1613619A1 Quinazoline derivatives for treatment of cancer |
| 01/11/2006 | EP1613603A2 Migrastatin analogs and uses thereof |
| 01/11/2006 | EP1613592A2 Hydroxamic acid compounds and methods of use thereof |
| 01/11/2006 | EP1613588A2 2-propylidene-19-nor-vitamin d compounds |
| 01/11/2006 | EP1613320A1 Dosage forms comprising ag013736 |
| 01/11/2006 | EP1613310A1 Imidazole derivatives for treatment of allergic and hyperproliferative disorders |
| 01/11/2006 | EP1613273A2 Recombinant il-9 antibodies and uses thereof |
| 01/11/2006 | EP1613268A2 Methods for inhibition of angiogenesis |
| 01/11/2006 | EP1491206A4 Induction method for cell differentiation |
| 01/11/2006 | EP1469887A4 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/11/2006 | EP1435986A4 Igf-binding protein-derived peptide or small molecule |
| 01/11/2006 | EP1421082B1 piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity |
| 01/11/2006 | EP1414481B1 Use of cetrorelix for the treatment of jacob-creutzfeldt-disease |
| 01/11/2006 | EP1407033B1 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva) |
| 01/11/2006 | EP1392830B1 Interleukin-18 mutants, their production and use |
| 01/11/2006 | EP1372723B1 Semi-allogenic anti-tumour vaccine with hla haplo-identical antigen-presenting cells |
| 01/11/2006 | EP1366036B1 Compounds having activity as inhibitors of cytochrome p450rai |
| 01/11/2006 | EP1358169B1 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase |
| 01/11/2006 | EP1341412B1 Indolocarbazole anticancer agents and methods of using them |
| 01/11/2006 | EP1303540B1 Multi-specific reagent for selective stimulation of cell surface receptors |
| 01/11/2006 | EP1296670B1 Therapeutic combinations of fatty acids |
| 01/11/2006 | EP1294924B1 Competitive assay for identifying allosteric inhibitors |